disability progression

ECTRIMS 2023: NMOSD disability progresses faster than in MOGAD

People with neuromyelitis optica spectrum disorder (NMOSD) experience faster disability progression with fewer attacks than those with myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD), a related condition, according to a long-term analysis of German registry data. Notably, in all patients, experiencing inflammation in the optic nerve, which transmits signals between…

NMOSD patient’s relapses, disability worsening halted with ofatumumab

Ofatumumab, a medication approved for multiple sclerosis (MS), effectively prevented relapses and disability progression in a 67-year old woman with neuromyelitis optica spectrum disorder (NMOSD) who failed to respond to rituximab, a Chinese case report described. Both ofatumumab and rituximab — often used off-label in NMOSD — promote the…

Developing NMOSD After Age 50 Linked to Worse Outcomes: Study

People who develop neuromyelitis optica spectrum disorder (NMOSD) later in life may go on to experience worse outcomes than those who have early-onset disease, a study in China has found. Worse outcomes included a higher frequency of inflammation of the thoracic spinal cord during relapses, more brain lesions and…

Study: Low Rituximab Dose Effective in Preventing Relapses in NMOSD

A low dose of rituximab — infused at 100 mg weekly for three consecutive weeks — was effective at preventing relapses and disability progression in people with neuromyelitis optica spectrum disorder (NMOSD), according to a meta-analysis of five different regimens. Moreover, treatment with rituximab at this low…